ArticleInflammation2026
Luteolin Attenuates Asthma Via Inhibiting ALOX15 Mediated Bronchial Epithelial Cell Ferroptosis.
Article in Inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Iron Lung: Ferroptosis and Iron Regulation in Aging and Lung Diseases.Physiology (Bethesda, Md.) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Ferroptosis, an iron-dependent form of cell death driven by lipid peroxidation, plays a critical role in the progression of asthma, yet its therapeutic modulation remains underexplored. Luteolin (Lut), a natural flavonoid known for its anti-inflammatory properties, presents a potential candidate for targeting ferroptosis in asthma. However, the precise mechanisms underlying its therapeutic effects are unclear. This study used a combination of bioinformatics, network pharmacology, molecular docking, and in vitro and in vivo experiments to investigate the role of luteolin in the treatment of ferroptosis in asthma. A collection of natural flavonoid compounds with high oral bioavailability and drug-like properties was assembled from the Chinese herbal medicine database. Through network pharmacology analysis, it was discovered that these flavonoids can effectively treat ferroptosis in asthma by regulating Arachidonic acid 15-lipoxygenase (ALOX15) and arachidonic acid metabolism. Further investigation through virtual docking revealed that luteolin is a key compound in the treatment of ferroptosis in asthma, targeting ALOX15. Molecular dynamics simulations demonstrated that the ALOX15-luteolin complex is stable and flexible. Cellular Thermal Shift Assay (CETSA) confirmed the thermal stability of luteolin and ALOX15, while Drug affinity response target stability (DARTS) assay showed that luteolin inhibits the proteolysis of ALOX15 by pronase. In in vitro experiments, it was observed that luteolin treatment reduced Fe
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.